Inhibitors of receptor activator of NF-kappaB and uses thereof
AssigneeResearch Development Corporation
InventorsBharat Aggarwal, Bryant G. Darnay, Sujay Singh
Life of this patent
Estimating the term…
Abstract
The present invention provides a RANK (receptor activator of NF-κB) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The peptide inhibitor inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
Claims25
A polypeptide that inhibits signaling mediated b y TNF receptor-associated factor 6 (TRAF6), wherein said polypeptide comprises a TRAF6 binding domain and a leader signal sequence.
A pharmaceutical composition comprising the polypeptide of claim I and a pharmaceutically acceptable carrier.
A non-peptide analog that mimics the function of a polypeptide comprising a TNF receptor-associated factor 6 (TRAF6) binding domain and a leader signal sequence, wherein said polypeptide inhibits signaling mediated by TRAF6.
Dependencies are inferred from the claim text.